{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:19:47Z","timestamp":1779365987277,"version":"3.53.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA041489"],"award-info":[{"award-number":["R21 DA041489"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["CDA 13-279"],"award-info":[{"award-number":["CDA 13-279"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["RCS 00-001"],"award-info":[{"award-number":["RCS 00-001"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["RCS 14-232"],"award-info":[{"award-number":["RCS 14-232"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11606-020-05944-6","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T16:03:23Z","timestamp":1593014603000},"page":"2529-2536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-7092","authenticated-orcid":false,"given":"Andrea K.","family":"Finlay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Stimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Timko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H. S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Blue-Howells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid A.","family":"Binswanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"issue":"3","key":"5944_CR1","first-page":"348","volume":"40","author":"HS Wortzel","year":"2012","unstructured":"Wortzel HS, Blatchford P, Conner L, Adler LE, Binswanger IA. Risk of death for veterans on release from prison. J Am Acad Psychiatry Law. 2012;40(3):348-54.","journal-title":"J Am Acad Psychiatry Law."},{"key":"5944_CR2","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ."},{"issue":"3","key":"5944_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018 Aug 7;169(3):137-45.","journal-title":"Ann Intern Med."},{"issue":"1","key":"5944_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/08897077.2011.609438","volume":"33","author":"DM Coviello","year":"2012","unstructured":"Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33(1):48-59.","journal-title":"Subst Abus."},{"issue":"6","key":"5944_CR5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1360-0443.2005.01050.x","volume":"100","author":"KA Dolan","year":"2005","unstructured":"Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820-8.","journal-title":"Addiction."},{"issue":"1","key":"5944_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08897077.2011.616816","volume":"33","author":"J Gryczynski","year":"2012","unstructured":"Gryczynski J, Kinlock TW, Kelly SM, O\u2019Grady KE, Gordon MS, Schwartz RP. Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Subst Abus. 2012;33(1):30-9.","journal-title":"Subst Abus."},{"issue":"2","key":"5944_CR7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/ADM.0b013e318284a0c1","volume":"7","author":"SM Kelly","year":"2013","unstructured":"Kelly SM, O\u2019Grady K E, Jaffe JH, Gandhi D, Schwartz RP. Improvements in outcomes in methadone patients on probation\/parole regardless of counseling early in treatment. J Addict Med. 2013;7(2):133-8.","journal-title":"J Addict Med."},{"issue":"4","key":"5944_CR8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/add.14059","volume":"113","author":"A Russolillo","year":"2018","unstructured":"Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018 Apr;113(4):656-67.","journal-title":"Addiction."},{"issue":"3","key":"5944_CR9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0595","volume":"2","author":"A Russolillo","year":"2019","unstructured":"Russolillo A, Moniruzzaman A, Somers JM. Association of methadone treatment with substance-related hospital admissions among a population in Canada with a history of criminal convictions. JAMA Netw Open. 2019;2(3):e190595.","journal-title":"JAMA Netw Open."},{"issue":"8","key":"5944_CR10","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14620","volume":"114","author":"EA Evans","year":"2019","unstructured":"Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019;114(8):1396-404.","journal-title":"Addiction."},{"issue":"2","key":"5944_CR11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1360-0443.2011.03618.x","volume":"107","author":"S Larney","year":"2012","unstructured":"Larney S, Toson B, Burns L, Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction. 2012;107(2):372-80.","journal-title":"Addiction."},{"issue":"12","key":"5944_CR12","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/add.13073","volume":"110","author":"N Gisev","year":"2015","unstructured":"Gisev N, Shanahan M, Weatherburn DJ, Mattick RP, Larney S, Burns L, et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction. 2015;110(12):1975-84.","journal-title":"Addiction."},{"key":"5944_CR13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2016.01.013","volume":"160","author":"AK Finlay","year":"2016","unstructured":"Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, et al. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients. Drug Alcohol Depend. 2016;160:222-6.","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"5944_CR14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13722-014-0023-0","volume":"10","author":"AD Fox","year":"2015","unstructured":"Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.","journal-title":"Addict Sci Clin Pract."},{"issue":"3","key":"5944_CR15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/dar.12442","volume":"36","author":"S Larney","year":"2017","unstructured":"Larney S, Zador D, Sindicich N, Dolan K. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug Alcohol Rev. 2017;36(3):305-10.","journal-title":"Australia. Drug Alcohol Rev."},{"issue":"1","key":"5944_CR16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","volume":"4","author":"MA Yokell","year":"2011","unstructured":"Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28-41.","journal-title":"Curr Drug Abuse Rev."},{"issue":"1","key":"5944_CR17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","volume":"13","author":"RA Rosenblatt","year":"2015","unstructured":"Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23-6.","journal-title":"Ann Fam Med."},{"issue":"5","key":"5944_CR18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","volume":"13","author":"EM Oliva","year":"2011","unstructured":"Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374-81.","journal-title":"Curr Psychiatry Rep."},{"issue":"6","key":"5944_CR19","doi-asserted-by":"crossref","first-page":"909","DOI":"10.15288\/jsad.2018.79.909","volume":"79","author":"AK Finlay","year":"2018","unstructured":"Finlay AK, Wong JJ, Ellerbe LS, Rubinsky A, Gupta S, Bowe TR, et al. Barriers and facilitators to implementation of pharmacotherapy for opioid use disorders in VHA residential treatment programs. J Stud Alcohol Drugs. 2018;79(6):909-17.","journal-title":"J Stud Alcohol Drugs."},{"issue":"1","key":"5944_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08897077.2011.611460","volume":"33","author":"PD Friedmann","year":"2012","unstructured":"Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9-18.","journal-title":"Subst Abus."},{"issue":"5","key":"5944_CR21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jsat.2012.10.004","volume":"44","author":"H Matusow","year":"2013","unstructured":"Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473-80.","journal-title":"J Subst Abuse Treat."},{"issue":"1","key":"5944_CR22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40352-019-0089-6","volume":"7","author":"J Reichert","year":"2019","unstructured":"Reichert J, Gleicher L. Probation clients\u2019 barriers to access and use of opioid use disorder medications. Health Justice. 2019;7(1):10.","journal-title":"Health Justice."},{"issue":"2","key":"5944_CR23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/10826084.2017.1342662","volume":"53","author":"K McElrath","year":"2018","unstructured":"McElrath K. Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. Subst Use Misuse. 2018;53(2):334-43.","journal-title":"Subst Use Misuse."},{"key":"5944_CR24","unstructured":"Department of Veterans Affairs. Uniform Mental Health Services in VA medical centers and clinics. VHA Handbook 1160.1. Washington, DC: US Department of Veterans Affairs, Veterans Health Administration; 2008."},{"issue":"1","key":"5944_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1037\/a0029652","volume":"10","author":"JH Blue-Howells","year":"2013","unstructured":"Blue-Howells JH, Clark SC, van den Berk-Clark C, McGuire JF. The U.S. Department of Veterans Affairs Veterans Justice Programs and the sequential intercept model: case examples in national dissemination of intervention for justice-involved veterans. Psychol Serv. 2013;10(1):48-53. doi:https:\/\/doi.org\/10.1037\/a0029652","journal-title":"Psychol Serv."},{"key":"5944_CR26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jsat.2018.09.006","volume":"95","author":"AK Finlay","year":"2018","unstructured":"Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, et al. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 Dec;95:43-7.","journal-title":"J Subst Abuse Treat."},{"key":"5944_CR27","doi-asserted-by":"crossref","unstructured":"Finlay AK, Harris AHS, Timko C, Yu M, Smelson D, Stimmel M, et al. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. Manuscript submitted for publication. 2019.","DOI":"10.1097\/ADM.0000000000000719"},{"issue":"4","key":"5944_CR28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017 Mar;27(4):591-608.","journal-title":"Qual Health Res."},{"key":"5944_CR29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Sci. 2009;4:50.","journal-title":"Implementation Sci."},{"issue":"2","key":"5944_CR30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1037\/a0022398","volume":"25","author":"JK Manuel","year":"2011","unstructured":"Manuel JK, Hagedorn HJ, Finney JW. Implementing evidence-based psychosocial treatment in specialty substance use disorder care. Psychol Addict Behav. 2011;25(2):225-37.","journal-title":"Psychol Addict Behav."},{"issue":"2","key":"5944_CR31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1037\/a0022765","volume":"25","author":"JL Sorensen","year":"2011","unstructured":"Sorensen JL, Kosten T. Developing the tools of implementation science in substance use disorders treatment: applications of the Consolidated Framework for Implementation Research. Psychol Addict Behav. 2011;25(2):262-8.","journal-title":"Psychol Addict Behav."},{"key":"5944_CR32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jsat.2017.03.005","volume":"77","author":"AK Finlay","year":"2017","unstructured":"Finlay AK, Ellerbe LS, Wong JJ, Timko C, Rubinsky AD, Gupta S, et al. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. J Subst Abuse Treat. 2017;77:38-43.","journal-title":"J Subst Abuse Treat."},{"key":"5944_CR33","unstructured":"Atlas.ti Scientific Software Development GmbH. Atlas.ti Version 8 [Computer Software]. Berlin, Germany: Scientific Software Development; 2019."},{"key":"5944_CR34","volume-title":"The Sage Handbook of Grounded Theory","year":"2010","unstructured":"Bryant A, Charmaz K, editors. The Sage Handbook of Grounded Theory. Newbury Park, CA: Sage Publications; 2010."},{"key":"5944_CR35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.drugalcdep.2017.08.019","volume":"180","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Tompkins DA, Dunn KE. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017 Nov 1;180:279-85.","journal-title":"Drug Alcohol Depend."},{"key":"5944_CR36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2016.02.009","volume":"66","author":"LA Uebelacker","year":"2016","unstructured":"Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients\u2019 beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016 Jul;66:48-53.","journal-title":"J Subst Abuse Treat."},{"issue":"3","key":"5944_CR37","volume":"1","author":"TNA Winkelman","year":"2018","unstructured":"Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.","journal-title":"JAMA Netw Open."},{"key":"5944_CR38","volume-title":"VA\/DoD clinical practice guideline for the management of substance use disorders","author":"Department of Veterans Affairs & Department of Defense","year":"2015","unstructured":"Department of Veterans Affairs & Department of Defense. VA\/DoD clinical practice guideline for the management of substance use disorders. Washington, DC: Authors; 2015."},{"key":"5944_CR39","volume":"10","author":"L Amato","year":"2011","unstructured":"Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011 (10):CD004147.","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"5944_CR40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","volume":"9","author":"K Kampman","year":"2015","unstructured":"Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-67.","journal-title":"J Addict Med."},{"issue":"2","key":"5944_CR41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","volume":"10","author":"K Dugosh","year":"2016","unstructured":"Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93-103.","journal-title":"J Addict Med."},{"issue":"4","key":"5944_CR42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/00952990.2019.1605372","volume":"45","author":"RP Winograd","year":"2019","unstructured":"Winograd RP, Presnall N, Stringfellow E, Wood C, Horn P, Duello A, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse. 2019;45(4):333-40.","journal-title":"Am J Drug Alcohol Abuse."},{"key":"5944_CR43","volume-title":"Wood CA","author":"RP Winograd","year":"2019","unstructured":"Winograd RP, Wood CA, Stringfellow EJ, Presnall N, Duello A, Horn P, et al. Implementation and evaluation of Missouri\u2019s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abuse Treat. 2019 Jun 26."},{"key":"5944_CR44","volume-title":"Housing First implementation brief","author":"AE Montgomery","year":"2014","unstructured":"Montgomery AE, Hill L, Culhane DP, Kane V. Housing First implementation brief. Washington, DC: VA National Center on Homelessness Among Veterans, U.S. Department of Veterans Affairs, 2014."},{"issue":"2","key":"5944_CR45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10597-018-0255-7","volume":"55","author":"D Smelson","year":"2019","unstructured":"Smelson D, Farquhar I, Fisher W, Pressman K, Pinals DA, Samek B, et al. Integrating a co-occurring disorders intervention in drug courts: an open pilot trial. Community Ment Health J. 2019;55(2):222-31.","journal-title":"Community Ment Health J."},{"key":"5944_CR46","first-page":"5","volume":"2","author":"LM Westreich","year":"2019","unstructured":"Westreich LM. Use of medication-assisted treatment in the justice system: a medical perspective. Journal for Advancing Justice. 2019;2:5-19.","journal-title":"Journal for Advancing Justice."},{"issue":"2","key":"5944_CR47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75.","journal-title":"Harv Rev Psychiatry."},{"issue":"4","key":"5944_CR48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11481-018-9801-x","volume":"13","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, et al. Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine\/naloxone in a multi-site trial. J Neuroimmune Pharmacol. 2018;13(4):488-97.","journal-title":"J Neuroimmune Pharmacol."},{"key":"5944_CR49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","volume":"57","author":"RE Clark","year":"2015","unstructured":"Clark RE, Baxter JD, Aweh G, O\u2019Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75-80.","journal-title":"J Subst Abuse Treat."},{"key":"5944_CR50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2019.01.019","volume":"100","author":"D Muthulingam","year":"2019","unstructured":"Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. J Subst Abuse Treat. 2019;100:18-28.","journal-title":"J Subst Abuse Treat."},{"issue":"1","key":"5944_CR51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/jrh.12328","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113-21.","journal-title":"J Rural Health."},{"key":"5944_CR52","first-page":"39","volume":"2","author":"JR Gallagher","year":"2019","unstructured":"Gallagher JR, Marlowe DB, Minasian RM. Participant perspectives on medication-assisted treatment for opioid use disorders in drug court. Journal for Advancing Justice. 2019;2:39-54.","journal-title":"Journal for Advancing Justice."},{"key":"5944_CR53","first-page":"93","volume":"2","author":"A Dorman","year":"2019","unstructured":"Dorman A, Badeti J, Boros A. An exploration of knowledge, opinions, and stigma regarding medication-assisted treatment among treatment and criminal justice professionals. Journal for Advancing Justice. 2019;2:93-108.","journal-title":"Journal for Advancing Justice."},{"key":"5944_CR54","first-page":"1","volume":"40","author":"KK Dineen","year":"2016","unstructured":"Dineen KK. Addressing prescription opioid abuse concerns in context: synchronizing policy solutions to multiple complex public health problems. Law & Psychol Rev. 2016;40:1.","journal-title":"Law & Psychol Rev."},{"issue":"1","key":"5944_CR55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12954-019-0301-y","volume":"16","author":"B Johnson","year":"2019","unstructured":"Johnson B, Richert T. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. Harm Reduct J. 2019;16(1):31.","journal-title":"Harm Reduct J."},{"key":"5944_CR56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7517-10-24","volume":"10","author":"IA Havnes","year":"2013","unstructured":"Havnes IA, Clausen T, Middelthon AL. \u2018Diversion\u2019 of methadone or buprenorphine: \u2018harm\u2019 versus \u2018helping\u2019. Harm Reduct J. 2013;10:24.","journal-title":"Harm Reduct J."},{"issue":"6","key":"5944_CR57","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.drugpo.2012.10.003","volume":"24","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of \u2018generous constraints\u2019. Int J Drug Policy. 2013;24(6):e43-50.","journal-title":"Int J Drug Policy."},{"key":"5944_CR58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","volume":"136","author":"B Larance","year":"2014","unstructured":"Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21-7.","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"5944_CR59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/02791072.2014.960109","volume":"46","author":"B Johnson","year":"2014","unstructured":"Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective. J Psychoactive Drugs. 2014;46(5):427-35.","journal-title":"J Psychoactive Drugs."},{"key":"5944_CR60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-015-0037-2","volume":"12","author":"T Richert","year":"2015","unstructured":"Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12:1.","journal-title":"Harm Reduct J."},{"key":"5944_CR61","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpsychires.2015.07.016","volume":"69","author":"AD Rubinsky","year":"2015","unstructured":"Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150-7.","journal-title":"J Psychiatr Res."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-05944-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-05944-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-05944-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:44:54Z","timestamp":1624495494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-05944-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5944"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-05944-6","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"26 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Stanford University Institutional Review Board and the VA Palo Alto Research & Development committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The views expressed in this article are those of the authors and do not necessarily reflect the position nor policy of the Department of Veterans Affairs (VA) or the US government. The VA had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}